In a separate clinical study (n = 6) by Oordt et al. using [89Zr]Zr-DFO-GSK2849330, another HER3-targeting antibody, it was observed that an 8 mg dose provided the best tumor contrast on day 5 post-injection. Here, ERBB3 is linked to neoplasm.